Crinetics Pharmaceuticals, Inc.
CRNX
$30.93
$0.842.79%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.39M | 760.00K | 1.04M | 1.04M | 1.39M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.39M | 760.00K | 1.04M | 1.04M | 1.39M |
| Cost of Revenue | 217.81M | 216.20M | 193.30M | 172.32M | 154.25M |
| Gross Profit | -216.42M | -215.44M | -192.26M | -171.28M | -152.87M |
| SG&A Expenses | 139.44M | 114.44M | 99.74M | 88.64M | 78.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 424.45M | 377.49M | 339.89M | 307.81M | 279.33M |
| Operating Income | -423.06M | -376.73M | -338.85M | -306.77M | -277.95M |
| Income Before Tax | -369.83M | -328.25M | -298.41M | -277.91M | -258.54M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -369.83 | -328.25 | -298.41 | -277.91 | -258.54 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -369.83M | -328.25M | -298.41M | -277.91M | -258.54M |
| EBIT | -423.06M | -376.73M | -338.85M | -306.77M | -277.95M |
| EBITDA | -419.62M | -373.49M | -336.07M | -304.51M | -276.19M |
| EPS Basic | -4.11 | -3.82 | -3.70 | -3.72 | -3.77 |
| Normalized Basic EPS | -2.57 | -2.39 | -2.31 | -2.32 | -2.36 |
| EPS Diluted | -4.11 | -3.82 | -3.70 | -3.72 | -3.77 |
| Normalized Diluted EPS | -2.57 | -2.39 | -2.31 | -2.32 | -2.36 |
| Average Basic Shares Outstanding | 358.48M | 343.70M | 322.88M | 298.53M | 275.25M |
| Average Diluted Shares Outstanding | 358.48M | 343.70M | 322.88M | 298.53M | 275.25M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |